ArticleScientific reports2026
Clinical characteristics, laboratory measures, and quality of life as predictors of medication adherence in multiple myeloma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medication adherence in multiple myeloma (MM) is a key determinant of treatment outcomes, yet its relationship with patient-reported quality of life (QOL) remains insufficiently studied. We conducted a multi-center cross-sectional study across five West Bank hospitals (2018–2025), enrolling 250 adults with MM on active treatment. At enrollment, patients completed the EORTC QLQ-MY20 to assess disease-specific QOL, and one month later, adherence was evaluated using the Morisky Medication Adherence Scale-4 (MMAS-4). Most patients demonstrated medium (38.4%) or high (41.6%) adherence. Symptom burden was considerable, with lower back pain (76.4%), joint pain (69.2%), bone pain (63.6%), and constitutional symptoms (60.0%) reported frequently. Ordinal logistic regression revealed that higher scores in functional domains were strongly associated with better adherence, specifically in the Future Perspective (aCoeff = 1.044, p < 0.001) and Body Image (aCoeff = 0.757, p < 0.001) domains. In contrast, higher symptom burden predicted lower adherence: Side Effects (aCoeff = -1.134; p < 0.001) and Disease Symptoms (aCoeff = -1.020; p < 0.001). No significant associations were observed with most demographic, comorbidity, or laboratory variables. These findings demonstrate that QOL domains are independent predictors of adherence in MM. Routine QOL monitoring may help identify patients at risk of non-adherence and inform supportive interventions to sustain therapy and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.